Compare Freeport-McMoRan Inc (FCX) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Freeport-McMoRan Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Freeport-McMoRan Inc trades at $73.56 (market cap $102.16B), while Vertex Pharmaceuticals Incorporated trades at $511.19 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is the larger of the two by market cap, and Freeport-McMoRan Inc pays a 0.84% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold Freeport-McMoRan Inc for 69 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| FCX | VRTX | |
|---|---|---|
Market Cap | $102.16B | $127.55B |
Volume | 9,047,971 | 1,487,944 |
Sector | Basic Materials | Health |
52-Week High | $79.91 | $557.96 |
52-Week Low | $38.65 | $407.37 |
Typical Hold Time | 69 Days | 120 Days |
Enterprise Value | $108.44B | $121.68B |
Dividend Yield | 0.84% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FCX trades at $73.29, up 1.98% on the day, with a bearish technical signal but strong fundamental support. The company has beaten EPS estimates for three consecutive quarters, with Q3 2026 results pending. Revenue is stable at $25.9B (2025), and net income margin improved to 11.38%. Analyst consensus is a Buy (60.97%), with a price target of $73.27. Recent news highlights copper demand growth driven by AI and data centers, positioning FCX to benefit.
FCX offers exposure to rising copper demand, supported by operational efficiency and expansion projects. Risks include cost pressures and regulatory scrutiny. The stock's valuation metrics (P/E 34.87, P/S 3.97) suggest premium pricing, requiring sustained earnings growth to justify upside. Institutional sentiment remains positive, but investors should monitor Q3 earnings and copper price trends.
Vertex Pharmaceuticals (VRTX) trades at $509.98, up 0.86% today, with a bearish technical signal but strong fundamentals. The company reported $12.00B revenue in 2025 with a 35% net income margin and robust cash flow. Recent positive Phase 2b data for inaxaplin in kidney disease and dominant cystic fibrosis market position support growth. Analysts maintain a strong buy consensus with a $573.50 price target, indicating 12% upside potential.
Outlook remains positive driven by pipeline expansion and high profitability, though risks include clinical trial outcomes and market volatility. The stock's valuation at 29.31 P/E is reasonable for its growth profile, but investor sentiment is cautious near-term due to mixed earnings beats and technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Freeport-McMoRan Inc
Freeport-McMoRan Inc is an international mining company. It operates geographically diverse assets with proven and probable mineral reserves of copper, gold and molybdenum. The company's portfolio of assets includes the Grasberg minerals district in Indonesia
Read more on FCX →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
